Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 23.63% is 35% above its 5-year average of 17.56%, near the high end of its 5-year range (-131.14%–27.46%).
8.74% above its 12-month average of 21.73%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): 17.54%.
EBITDA MARGIN
23.63%
EBITDA MARGIN AVG TTM
21.73%
EBITDA MARGIN AVG 3Y
18.90%
EBITDA MARGIN AVG 5Y
17.56%
EBITDA MARGIN AVG 10Y
9.97%
EBITDA MARGIN AVG 15Y
8.13%
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+8.74%
CURRENT VS 3Y AVG
+25.03%
CURRENT VS 5Y AVG
+34.59%
CURRENT VS 10Y AVG
+136.97%
CURRENT VS 15Y AVG
+190.57%
CURRENT VS 20Y AVG
N/A
Market Cap
$87.86M
EBITDA Margin
-8103.88%
TTM Avg
-7583.93%
3Y Avg
-8667.05%
5Y Avg
-7944.60%
Market Cap
$84.75M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$84.70M
EBITDA Margin
31.45%
TTM Avg
-14.67%
3Y Avg
-906.21%
5Y Avg
-1050.55%
Market Cap
$83.96M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$91.33M
EBITDA Margin
-35.83%
TTM Avg
-39.56%
3Y Avg
-111.97%
5Y Avg
-250.85%
Market Cap
$91.68M
EBITDA Margin
-19.79%
TTM Avg
-29.84%
3Y Avg
-150.95%
5Y Avg
-150.95%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CareCloud, Inc. (CCLD) | $86.69M | 23.63% | 21.73% | 18.90% | 17.56% |
| Cardiff Oncology, Inc. (CRDF)vs › | $87.86M | -8103.88% | -7583.93% | -8667.05% | -7944.60% |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $84.75M | N/A | N/A | N/A | N/A |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $84.70M | 31.45% | -14.67% | -906.21% | -1050.55% |
| Cognition Therapeutics, Inc. (CGTX)vs › | $83.96M | N/A | N/A | N/A | N/A |
| Conexeu Sciences Inc. (CNXU)vs › | $83.49M | N/A | N/A | N/A | N/A |
| electroCore, Inc. (ECOR)vs › | $91.33M | -35.83% | -39.56% | -111.97% | -250.85% |
| Equillium, Inc. (EQ)vs › | $91.68M | -19.79% | -29.84% | -150.95% | -150.95% |
| Citius Oncology, Inc. (CTOR)vs › | $81.22M | N/A | N/A | N/A | N/A |
| Biomea Fusion, Inc. (BMEA)vs › | $93.99M | N/A | N/A | N/A | N/A |
Gross Margin
46.5%
EBITDA Margin
23.6%
Operating Margin
7.3%
Net Margin
6.2%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | 17.54% |
| 2026-03-31 | 17.77% |
| 2025-12-31 | 26.33% |
| 2025-09-30 | 23.47% |
| 2025-06-30 | 23.54% |
| 2025-03-31 | 19.64% |
| 2024-12-31 | 23.77% |
| 2024-09-30 | 22.79% |
| 2024-06-30 | 21.61% |
| 2024-03-31 | 15.98% |
| 2023-12-31 | -131.14% |
| 2023-09-30 | 6.96% |
| 2023-06-30 | 7.39% |
| 2023-03-31 | 9.94% |
| 2022-12-31 | 22.86% |
| 2022-09-30 | 13.79% |
| 2022-06-30 | 15.67% |
| 2022-03-31 | 12.16% |
| 2021-12-31 | 27.46% |
| 2021-09-30 | 13.30% |
| 2021-06-30 | 9.20% |
| 2021-03-31 | 4.25% |
| 2020-12-31 | 11.64% |
| 2020-09-30 | 8.18% |
| 2020-06-30 | -12.62% |
| 2020-03-31 | -6.10% |
| 2019-12-31 | 9.37% |
| 2019-09-30 | 8.90% |
| 2019-06-30 | 3.39% |
| 2019-03-31 | 3.55% |
| 2018-12-31 | 0.44% |
| 2018-09-30 | -5.64% |
| 2018-06-30 | 7.28% |
| 2018-03-31 | 7.58% |
| 2017-12-31 | 2.51% |
| 2017-09-30 | 5.18% |
| 2017-06-30 | 0.90% |
| 2017-03-31 | -10.83% |
| 2016-12-31 | -24.75% |
| 2016-09-30 | -2.84% |
| 2016-06-30 | 2.58% |
| 2016-03-31 | -11.56% |
| 2015-12-31 | 10.95% |
| 2015-09-30 | -2.50% |
| 2015-06-30 | -5.01% |
| 2015-03-31 | -0.12% |
| 2014-12-31 | 6.95% |
| 2014-09-30 | -26.23% |
| 2014-06-30 | -4.50% |
| 2014-03-31 | -2.02% |
| 2013-12-31 | 17.78% |
| 2013-09-30 | 3.21% |
| 2013-06-30 | 1.03% |
| 2013-03-31 | 8.22% |
| 2012-12-31 | 8.93% |
| 2012-09-30 | 10.77% |
